Navigation Links
Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
Date:9/14/2009

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virologic suppression and increased CD4 cell counts, and was generally well tolerated over two years of therapy. These 96-week results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).(1)

The study involved 85 treatment-experienced HIV-infected patients who received 48 weeks of open-label vicriviroc (30 mg once daily) plus an optimized antiretroviral regimen containing a ritonavir-boosted protease inhibitor after completion of 48 weeks of treatment in the double-blind phase of the VICTOR-E1 study (total of 96 weeks). More than half of these patients began open-label treatment with undetectable virus, i.e. an HIV-1 RNA level of less than 50 copies/mL, and about two-thirds had less than 400 copies/mL. Seventy patients remained on therapy at the time of the 96-week analysis. The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period.

The data also showed that vicriviroc was generally well tolerated in this highly treatment-experienced population.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
2. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
3. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
4. Schering-Plough Announces Results of the Early ACS Trial
5. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
9. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
10. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
11. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today reported ... 2011. "We are focused on submitting our ... letter around year-end and filing the lorcaserin marketing authorization ... half of next year," stated Jack Lief, Arena,s President ...
... Nov. 9, 2011 Jay Yadav, M.D. , ... of the Year Award by the Association of Telecom ... medical device company that has developed and is commercializing ... human body. Dr. Yadav won the award in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 2The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 3
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... healthcare communities throughout ... ... of,Health IT Conference and Exhibition in Copenhagen, Microsoft Corp. and the,Healthcare ... Health Users Group (Microsoft HUG) across,Europe, the Middle East and Africa ...
... 4 Kaiser Foundation Health Plan,Inc., Kaiser Foundation ... of $10.2 billion for the quarter ended September,30, ... period last year., KFHP/H,s operating income in ... million in the same quarter last year. Financial ...
... Calif., Nov. 4 XTENT, Inc.,(Nasdaq: XTNT ) today ... September 30, 2008., The company reported a net loss ... of 2008, compared to a net loss of $9.5 million, ... the nine months ended,September 30, 2008, XTENT had a net ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (the ... had received a NASDAQ Staff Deficiency Letter indicating ... 4310(c)(7). This rule,requires the Company to maintain a ... on the NASDAQ Capital Market. For purposes of ...
... VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated ... 2008 to,discuss its 2008 third quarter financial results., ... To participate in the conference call, please dial ... at least 15 minutes,before the start of the call. ...
... N.Y. -- Researchers at the University at Buffalo have ... in utero to develop obesity in adulthood. , Moreover, ... metabolic programming occurs in the fetal hypothalamus, the area ... homeostasis (body weight) throughout life. , Levels of the ...
Cached Medicine News:Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 2Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 4Health News:XTENT Announces Third Quarter 2008 Financial Results 2Health News:XTENT Announces Third Quarter 2008 Financial Results 3Health News:XTENT Announces Third Quarter 2008 Financial Results 4Health News:WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7) 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Maternal obesity can program fetal brain to induce adult-onset obesity 2
Inquire...
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Single-action scissors offer fine-pointed, sharp dissecting jaws to facilitate a partial cut in the cystic duct in preparation for a cholangiogram. They are tapered at the tip for greater visualizati...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: